4SC Presents Update on Phase II SHELTER trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium
PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--Jan 21, 2011 - 4SC (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, will today present a poster update on the Phase II SHELTER trial in hepatocellular carcinoma (HCC) with the oral pan-histone deacetylase (HDAC) inhibitor resminostat. The poster will be presented by the lead investigator, Professor Dr. Michael Bitzer, at the 2011 Gastrointestinal Cancer Symposium (co-sponsored by the American Society of Clinical Oncology - ASCO, the American Society of Radiation Oncology - ASTRO and the Society of Surgical Oncology - SSO) on 20-21 January in San Francisco, USA.
Abstract: #71271: Titel: Clinical update on the SHELTER study: A phase I/II trial of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC) Session date and time: 21 January 2011, 11:45 am - 1.15 pm, Poster Session B: Pancreas, Small Bowel and Hepatobiliary Tract Poster Presenter: M. Bitzer, M. Horger, T. Ganten, M.P.Ebert, M.A. Woerns, M.M. Dollinger, A. Kirsch, G. Gerken, M.E. Scheulen, R. Jankowsky, A. Mais, B. Hauns, B. Hentsch, U.M. Lauer
- Ends -
About Resminostat (4SC-201)
Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor. HDAC inhibitors modify the DNA structure of tumour cells to cause their differentiation and programmed cell death (apoptosis) and are therefore considered to offer a mechanism of action that has the particular potential to halt tumour progression and induce tumour regression. Resminostat is currently also in a Phase II study as a second line treatment for advanced hepatocellular carcinoma and KRAS-mutant colorectal patients and as a third-line treatment in Hodgkin's lymphoma. In a completed Phase I trial in patients with various different cancer types, stable disease was achieved in over 50% of the patients, whilst the treatment was well tolerated and showed a positive, differentiating pharmacological profile to other drugs in this class.
4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in Phase II development in rheumatoid arthritis and inflammatory bowel disease (IBD), for which positive results from a Phase IIa study were recently reported. The company's lead oncology compound, resminostat (4SC-201), a pan-histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma, Hodgkin's lymphoma and KRAS-mutant colorectal cancer. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
For further information, please visit www.4sc.com.
This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.
End of Corporate News
|Am Klopferspitz 19a|
|Phone:||+49 (0)89 7007 63-0|
|Fax:||+49 (0)89 7007 63-29|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart|
Contact: 4SC AG
Investor & Public Relations
Tel.: +49 (0) 89 70 07 63 - 66
Tel.: +49 (0) 89 21 02 28 - 30
The Trout Group (USA)
Tel.: +1 646 378 2947
Posted: January 2011